GlaxoSmithKline
GSK
$39.34
Share price
-0.94%
Change (1 day)
-3.23%
Change (1 year)
Categories
Market capitalization of GlaxoSmithKline (GSK)
Market cap: $80.83 Billion USD
As of June 2025 GlaxoSmithKline has a market cap of $80.83 Billion USD. This makes GlaxoSmithKline the world's 246th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of GlaxoSmithKline from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | $80.83 B | 16.25% |
| 2024 | $69.53 B | -8.81% |
| 2023 | $76.25 B | 6% |
| 2022 | $71.93 B | -34.07% |
| 2021 | $109.10 B | 18.9% |
| 2020 | $91.76 B | -21.15% |
| 2019 | $116.38 B | 23.9% |
| 2018 | $93.93 B | 6.6% |
| 2017 | $88.11 B | -6.48% |
| 2016 | $94.22 B | -4.88% |
| 2015 | $99.05 B | -4.91% |
| 2014 | $104.16 B | -19.26% |
| 2013 | $129.00 B | 21.97% |
| 2012 | $105.76 B | -8.18% |
| 2011 | $115.19 B | 13.05% |
| 2010 | $101.89 B | -7.08% |
| 2009 | $109.65 B | 13.45% |
| 2008 | $96.66 B | -30.35% |
| 2007 | $138.78 B | -8.6% |
| 2006 | $151.83 B | 3.03% |
| 2005 | $147.36 B | 4.74% |
| 2004 | $140.69 B | 6.84% |
| 2003 | $131.68 B | 16.71% |
| 2002 | $112.83 B | -26.62% |
| 2001 | $153.76 B | -12.71% |
| 2000 | $176.16 B | 73.19% |
| 1999 | $101.71 B | -19.27% |
| 1998 | $125.99 B | 47.23% |
| 1997 | $85.57 B | 52.03% |
| 1996 | $56.28 B |
End of Day market cap according to different sources
On Jun 17th, 2025 the market cap of GlaxoSmithKline was reported to be:
$81.33 Billion USD
$81.84 Billion USD
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 AstraZeneca AZN | $228.06 B | 182.14% | 🇬🇧 UK |
 Pfizer PFE | $136.90 B | 69.37% | 🇺🇸 USA |
 Merck MRK | $200.88 B | 148.52% | 🇺🇸 USA |
 Novartis NVS | $231.54 B | 186.45% | 🇨🇭 Switzerland |
 Sanofi SNY | $119.59 B | 47.95% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | $20.18 B | -75.02% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | $1.26 B | -98.44% | 🇺🇸 USA |